The Library
Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study) : rationale and design of the MET-REMODEL study
Tools
Mohan, Mohapradeep, McSwiggan, Stephen, Baig, Fatima, Rutherford, Lynn and Lang, Chim C. (2015) Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study) : rationale and design of the MET-REMODEL study. Cardiovascular Therapeutics, 33 (1). pp. 1-8. doi:10.1111/1755-5922.12101 ISSN 1755-5922.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: https://doi.org/10.1111/1755-5922.12101
Abstract
Left ventricular hypertrophy (LVH) is a common and independent risk factor for cardiovascular events in patients with coronary artery disease (CAD). Controlling blood pressure is the standard approach to the management of LVH, but this is only partially effective as LVH also persists in normotensive patients. Apart from blood pressure (BP), other main risk factors associated with LVH are insulin resistance (IR) and central obesity. The diabetic medication, Metformin, reduces IR and aids weight loss and may therefore regress LVH. The MET REMODEL study will investigate the ability of Metformin to regress LVH in 64 patients with CAD. The MET‐REMODEL trial is a single‐center, phase IV, double blind, randomized, placebo‐controlled trial to investigate the efficacy of Metformin in regression of the independent cardiac risk factor of LVH in patients with CAD who are insulin resistant. A minimum of 64 adults with a history of CAD with LVH and IR will be randomized into two groups to receive, either Metformin XL or placebo. The primary endpoint of this trial is to investigate any change in left ventricular mass index. Secondary endpoints include changes to insulin resistance measured using fasting insulin resistance index (FIRI), obesity, LV size, and function and improvement in endothelial function. A positive result will assist clinicians to identify a new mechanism for LVH regression by administering Metformin XL. This may also lead to investigating the mortality benefit of Metformin in patients with CAD and LVH.
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Mental Health and Wellbeing Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
Journal or Publication Title: | Cardiovascular Therapeutics | ||||
Publisher: | Wiley-Blackwell Publishing, Inc | ||||
ISSN: | 1755-5922 | ||||
Official Date: | February 2015 | ||||
Dates: |
|
||||
Volume: | 33 | ||||
Number: | 1 | ||||
Page Range: | pp. 1-8 | ||||
DOI: | 10.1111/1755-5922.12101 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Open Access (Creative Commons) | ||||
Description: | Free Access |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |